Bank of New York Mellon’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-423,337
| Closed | -$9.19M | – | 4359 |
|
|
2017
Q2 | $9.19M | Sell |
423,337
-37,777
| -8% | -$686K | ﹤0.01% | 2015 |
|
|
2017
Q1 | $6.47M | Buy |
461,114
+26,039
| +6% | +$426K | ﹤0.01% | 2199 |
|
|
2016
Q4 | $8.16M | Buy |
435,075
+81,869
| +23% | +$1.39M | ﹤0.01% | 2061 |
|
|
2016
Q3 | $5.83M | Sell |
353,206
-19,279
| -5% | -$286K | ﹤0.01% | 2163 |
|
|
2016
Q2 | $5.01M | Sell |
372,485
-14,081
| -4% | -$205K | ﹤0.01% | 2210 |
|
|
2016
Q1 | $5.91M | Buy |
386,566
+25,281
| +7% | +$396K | ﹤0.01% | 2093 |
|
|
2015
Q4 | $7.17M | Sell |
361,285
-5,642
| -2% | -$107K | ﹤0.01% | 2015 |
|
|
2015
Q3 | $6.39M | Buy |
366,927
+65,085
| +22% | +$1.33M | ﹤0.01% | 2099 |
|
|
2015
Q2 | $6.1M | Buy |
301,842
+47,174
| +19% | +$910K | ﹤0.01% | 2237 |
|
|
2015
Q1 | $4.48M | Buy |
254,668
+47,335
| +23% | +$807K | ﹤0.01% | 2367 |
|
|
2014
Q4 | $3.38M | Sell |
207,333
-33,277
| -14% | -$611K | ﹤0.01% | 2527 |
|
|
2014
Q3 | $5.31M | Buy |
240,610
+40,487
| +20% | +$829K | ﹤0.01% | 2277 |
|
|
2014
Q2 | $4.03M | Buy |
200,123
+71,601
| +56% | +$1.21M | ﹤0.01% | 2446 |
|
|
2014
Q1 | $2.39M | Sell |
128,522
-87,998
| -41% | -$1.21M | ﹤0.01% | 2773 |
|
|
2013
Q4 | $2.18M | Buy |
216,520
+15,578
| +8% | +$188K | ﹤0.01% | 2835 |
|
|
2013
Q3 | $2.59M | Buy |
200,942
+26,451
| +15% | +$325K | ﹤0.01% | 2682 |
|
|
2013
Q2 | $2.07M | Buy |
+174,491
| New | +$1.89M | ﹤0.01% | 2765 |
|
Other funds holding AMRI
Bank of New York Mellon's AMRI Position: Q3 2017 in Review
Bank of New York Mellon sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 423,337 shares — an estimated $9.19M sold.
Bank of New York Mellon first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $9.19M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Bank of New York Mellon reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Bank of New York Mellon sold 423,337 Albany Molecular Research Inc shares in Q3 2017, an estimated $9.19M.
- Bank of New York Mellon first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Bank of New York Mellon's Albany Molecular Research Inc position peaked at $9.19M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Bank of New York Mellon's 13F filing for Q3 2017, filed 6 Nov 2017.